Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Palatin's LeuTech Clinically Useful For Appendicitis Diagnosis - FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Clinical management decisions on whether to use computed tomography (CT) or Palatin's LeuTech imaging agent for detecting appendicitis in patients with equivocal appendicitis likely will depend on an institution's level of expertise with each modality.
Advertisement

Related Content

Palatin Obtains Imaging Agent Approval, Aims For General Infection Nod
Palatin Obtains Imaging Agent Approval, Aims For General Infection Nod
One Year Later, Mallinckrodt Divestment Options Still Open For Tyco
One Year Later, Mallinckrodt Divestment Options Still Open For Tyco
Mallinckrodt Nellcor Puritan Bennett Line Breathes New Air Into Tyco
Mallinckrodt Nellcor Puritan Bennett Line Breathes New Air Into Tyco
Molecular Biosystems Weighing Options After Palatin Exits Merger Talks
In Brief: Immunomedics' LeukoScan
Advertisement
UsernamePublicRestriction

Register

MT013627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel